SEARCH

SEARCH BY CITATION

References

  • 1
    Hussain Z, Quigley EM. Complementary and alternative medicine in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 46571.
  • 2
    Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in IBS: a randomised controlled trial. Gut 2004; 53: 145964.
  • 3
    Zar S, Mincher L, Benson MJ, Kumar D. Food specific IgG4 antibodies guided exclusion diet improves symptoms and rectal compliance in IBS. Scand J Gastroenterol 2005; 40: 8007.
  • 4
    Quigley EM. The use of probiotics in functional bowel disease. Gastroenterol Clin North Am 2005; 34: 53345.
  • 5
    McCarthy J, O'Mahony L, O'Callaghan L et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 97580.
  • 6
    Madsen K, Cornish A, Soper P et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 58091.
  • 7
    Hart AL, Lammers K, Brigidi P et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004; 53: 16029.
  • 8
    O'Mahony L, McCarthy J, Kelly P, Shanahan F, Quigley EM. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 54151.
  • 9
    O'Mahony L, O'Callaghan L, McCarthy J et al. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol 2006; 290: G83945.
  • 10
    Jijon H, Backer J, Diaz H et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126: 135873.
  • 11
    Drisko J, Bischoff B, Giles C, Adelson M, Rao RV, McCallum R. Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 2005; 50: 11137.
  • 12
    Madden JA, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002; 88 (Suppl. 1): S6772.
  • 13
    Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 37382.
    Direct Link:
  • 14
    King TS, Elia M, Hunter JO. Abnormal colonic fermentation in the irritable bowel syndrome. Lancet 1998; 352: 11879.
  • 15
    Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 8528.
  • 16
    Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test suggesting bacterial overgrowth. Dig Dis Sci 2002; 47: 263942.
  • 17
    Pimentel M, Chow E, Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 4129.
  • 18
    Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaxamin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 32633.
    Direct Link:
  • 19
    Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics and probiotics. Gastroenterology 2006; 130 (Suppl. 1): S7890.
  • 20
    Johanson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 12318.
    Direct Link:
  • 21
    Kim HJ, Camilleri M, McKenzie S, Lempke MB, Burton DD. A randomized controlled trail of a probiotic, VSL#3 on gut transit and symptoms in diarrhoea-predominant IBS. Aliment Pharmacol Ther 2003; 17: 895904.
  • 22
    Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating. Neurogastroenterol Motil 2005; 17: 68796.
  • 23
    Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 38794.
  • 24
    Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome – a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 92531.
  • 25
    Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5: 16974.
  • 26
    Sen S, Mulan MM, Parker TJ, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 261520.
  • 27
    Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005; 147: 197201.
  • 28
    Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001; 152: 73541.
  • 29
    Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005; 3: 77788.
  • 30
    Castigliuolo I, Riegler MF, Valenick L, La Mont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 3027.
  • 31
    Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124: 166271.
  • 32
    Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004; 2: CD003048.
  • 33
    Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 80411.
  • 34
    Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 16519.
  • 35
    Chadwick V, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 177883.
  • 36
    Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 30411.
  • 37
    Khalif IL, Quigley EM, Konovitch EA, Maximova ID. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 2005; 37: 83849.
  • 38
    Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 5208.
  • 39
    Quigley EM. Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. Gastroenterol Clin North Am 2005; 34: 22133.
  • 40
    Bouin M, Plourde V, Boivin M et al. Rectal distension testing in patients with the irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 17717.
  • 41
    Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002; 122: 207880.
  • 42
    Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693702.
  • 43
    Verdu EF, Bercik P, Bergonzelli GE et al. Lactobacillus paracasei normalizes muscle hypercontractiltiy in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127: 82637.
  • 44
    Verdu EF, Bercik P, Verma-Gandhu M et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 18290.
  • 45
    Ait-Belgnaoui A, Han W, Lamine F et al. Lactobacillus farciminis treatment suppresses stress-induced visceral hypersensitivity: a possible action through interaction with epithelial cells cytoskeleton contraction. Gut 2006; 55: 10904.
  • 46
    Kamiya T, Wang L, Forsythe P et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague–Dawley rats. Gut 2006; 55: 1916.
  • 47
    Zareie M, Johnson-Henry KC, Jury J, Yang PC, Ngan BY, McKay DM, Soderholm JD, Perdue MH, Sherman PM. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55: 155360.
  • 48
    Beishuizen A, Thijs LG. Endotoxin and the hypothalamic-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003; 9: 324.
  • 49
    Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 34350.
  • 50
    Sheil B, McCarthy J, O'Mahony L et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004; 53: 694700.
  • 51
    Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 11437.
  • 52
    Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with lacteol fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91: 157985.
  • 53
    O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 3024.
  • 54
    Nobaek S, Johanson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 12318.
    Direct Link:
  • 55
    Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 2001; 13: 2126.
  • 56
    Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101: 158190.
    Direct Link:
  • 57
    Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; 1: CD003960 (doi: DOI: 10.1002/14651858.CD003960.pub2).
  • 58
    Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 7986.